Smith & Nephew/£SN
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Smith & Nephew
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Ticker
£SN
Sector
Trading on
LSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
17,349
ISIN
GB0009223206
Website
Smith & Nephew Metrics
BasicAdvanced
£9.4B
30.74
£0.35
0.62
£0.29
2.67%
Price and volume
Market cap
£9.4B
Beta
0.62
52-week high
£12.45
52-week low
£9.11
Average daily volume
2.4M
Dividend rate
£0.29
Financial strength
Current ratio
2.888
Quick ratio
1.329
Long term debt to equity
61.88
Total debt to equity
63.077
Dividend payout ratio (TTM)
79.37%
Interest coverage (TTM)
4.53%
Management effectiveness
Return on assets (TTM)
5.44%
Return on equity (TTM)
7.86%
Valuation
Price to earnings (TTM)
30.736
Price to revenue (TTM)
2.171
Price to book
1.77
Price to tangible book (TTM)
7.73
Price to free cash flow (TTM)
20.808
Dividend yield (TTM)
2.67%
Growth
Revenue change (TTM)
4.70%
Earnings per share change (TTM)
56.15%
3-year revenue growth (CAGR)
3.69%
3-year earnings per share growth (CAGR)
-7.66%
What the Analysts think about Smith & Nephew
Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.
Smith & Nephew Financial Performance
Revenues and expenses
Smith & Nephew Earnings Performance
Company profitability
Smith & Nephew News
AllArticlesVideos
Smith+Nephew to showcase its CORI™ Surgical System at surgical clinics across Germany, Austria and Switzerland
GlobeNewsWire·4 weeks ago
Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript
Seeking Alpha·4 weeks ago
Smith & Nephew shares jump 7% on better-than-expected quarterly growth
Proactive Investors·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Smith & Nephew stock?
Smith & Nephew (SN) has a market cap of £9.4B as of May 30, 2025.
What is the P/E ratio for Smith & Nephew stock?
The price to earnings (P/E) ratio for Smith & Nephew (SN) stock is 30.74 as of May 30, 2025.
Does Smith & Nephew stock pay dividends?
Yes, the Smith & Nephew (SN) stock pays dividends to shareholders. As of May 30, 2025, the dividend rate is £0.2858 and the yield is 2.67%. Smith & Nephew has a payout ratio of 79.37% on a trailing twelve-month basis.
When is the next Smith & Nephew dividend payment date?
The next Smith & Nephew (SN) dividend payment date is unconfirmed.
What is the beta indicator for Smith & Nephew?
Smith & Nephew (SN) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.